AI
After AI’s magic wand status, it's now come to Google and Open AI CEOs talking of the likelihood of a bubble burst. In this interview, Parexel’s India head discusses how to view returns on such investments, the CRO’s own use cases and the US FDA’s keenness on transparency and open dialogue.
CRDMOs, CDMOs and GCCs are driving partnering and invigorating the wider ecosystem as India moves up the innovation value chain. CRDMOs are moving well beyond traditional outsourcing roles, a new report shows.
Deal Snapshot: Merck KGaA is looking to bolster its neuroscience pipeline with novel drugs for Parkinson’s disease and will team with Valo Health on AI-driven discovery work.
Senior Indegene executive discusses why pharma R&D organizations of the future will need to be agile, modular and AI-native by design. Industry pilots are pointing the way to potential one click regulatory submissions.
Experts from UCB, Alnylam, Lantheus and Medtronic deliberated at a recent summit best uses of agentic AI in the MLR review process, its human replaceability quotient and ways to balance creativity with compliance, a significant discussion amid DTC advertising and US FDA scrutiny.
At the annual biopharma confab, biopharma execs shared their thoughts about where artificial intelligence is heading and pharma avoiding following the leader in hot areas.
The drugmaker announced it would work with the tech giant to deploy a supercomputer that it will use to train AI models and enhance drug discovery, development and manufacturing.
One panelist at the BioFuture conference said AI is a bubble, but that when the bubble bursts it will leave a lot of innovation in its wake.
Speakers at the BioFuture conference discussed how confusing the policy environment has become, skepticism about AI/ML in drug development, the future of cancer immunotherapy, ideas for accelerating rare disease therapies and where the biopharma financing market is going.
Takeda's APAC chief talks about driving affordability and access for products like Adcetris and Qdenga, focusing on the region's diverse needs. “Watch this space” he said on the Japanese group’s Innovation Capability Centers, as they shape digital solutions to transform operations.
The drugmaker launched TuneLab, part of Catalyze360, which gives partners access to its artificial intelligence/machine learning drug discovery model trained on its research data.
Key opinion leaders share their perspectives on how transformative technologies like AI will significantly impact the biopharma industry in 2025.
A July white paper from Lifescience Dynamics explores the potential ways AI could see usage in pricing, reimbursement and market access for biopharma companies.
CEO Robert Bradway expressed support on the company’s Q2 earnings call for lower drug prices but said it was “premature” to comment in detail on particular proposals.
While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.
As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges